Sirtex Medical Ltd. | Mutual Funds
Mutual Funds that own Sirtex Medical Ltd.
Hunter Hall Value Growth Trust
1,456,198
2.61%
1,456,198
6.95%
06/30/2016
Allan Gray Australia Equity Fund
1,085,774
1.95%
1,085,774
2.21%
12/31/2017
Government Pension Fund - Global (The)
1,071,365
1.92%
229,290
0%
12/31/2017
Hunter Hall Global Value Ltd.
813,453
1.46%
-931,814
6.79%
06/30/2016
Vanguard Total International Stock Index Fund
649,071
1.15%
0
0%
07/31/2018
634,676
1.13%
122,200
0.95%
06/30/2017
DFA Asia Pacific Small Company Series
549,789
0.99%
42,145
0.63%
01/31/2018
Arbitrage Fund (The)
537,500
0.96%
537,500
1.21%
02/28/2018
Vanguard Australian Shares Index Fund
415,314
0.74%
5,515
0.11%
07/31/2018
Vanguard Developed Markets Index Fund
261,371
0.47%
0
0.01%
07/31/2018
| Address |
101 Miller Street
North Sydney New South Wales (NSW) 2060
Australia
|
|
Employees
|
- |
| Website |
http://www.sirtex.com |
| Updated |
09/14/2018 |
| Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres. Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC. |
